Half-Year re­sults 2023

Safe Harbor Statement

This written statement and oral statements or other statements made, or to be made, by us contain forward-looking statements that do not relate solely to historical or current facts. These forward-looking statements are based on the current plans and expectations of our management and are subject to a number of uncertainties and risks that could significantly affect our current plans and expectations, as well as future results of operations and financial condition. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Agenda

Media and financial analysts conference call H1 2023

• Highlights H1 2023
  Martin Schaufelberger, CEO
• Financials H1 2023 Markus Abderhalden, CFO
• Outlook
  Martin Schaufelberger, CEO
• Q&A All

Highlights H1 2023

Record free cash flow and strong balance sheet basis for further growth

• Key figures • Net sales CHF 131.4 m (PY CHF 134.9 m); +1.7% adjusted by FX and -2.6% in CHF
• • EBIT margin at 11.0% (PY 12.4%)
  • Net profit amounted to CHF 10.0 m (PY CHF 12.1 m)
  • Free Cash Flow at CHF 16.7 m (PY CHF 7.8 m)
• Operational • Backlog situation of devices in Infection Control mostly solved
• • Delays by the notified body caused negative impact on Endo business
  • Due to strict cost management, operating costs were reduced by 4.7%
  • COLTENE is well prepared for the new European Medical Device Regulation (MDR) and meets already the high product and process quality requirement for most of its business
  • Increasing patient safety thanks to the new traceability system of the reprocessing of instruments based on the digital platform my.coltene
  • Implementation of non-financial reporting requirements and projects for reduction of CO2 emission
• Organizational • Gregor Picard started as new COO as per 1st April replacing Stefan Helsing due to retirement